Calls
3
Madison Muller
Bloomberg Reporter
Win Rate
66.7%
return
+6.5%
Loading charts...
Ticker
Side
Mentions
First Call
Call Price
P&L
Thesis
Theme
Source
Long
Aug 19
$123.83
+19.2%
Merck and Moderna's personalized mRNA melanoma vaccine succeeded in a large late-stage trial, significantly reducing melanoma recurrence. This validates the mRNA cancer vaccine platform and, for Moderna, suggests a future beyond COVID with a potentially steady revenue stream if approved next year, and investors are already re-rating the shares.
Pharma & Biotech
Long
Aug 19
$147.64
+2.7%
Merck and Moderna's personalized mRNA melanoma vaccine succeeded in a large late-stage trial, significantly reducing melanoma recurrence. This validates the mRNA cancer vaccine platform and, for Moderna, suggests a future beyond COVID with a potentially steady revenue stream if approved next year, and investors are already re-rating the shares.
Pharma & Biotech
Long
Jul 23
$1188.00
-2.4%
Retatrutide is a next-generation triple-agonist weight loss shot combining GLP-1, glucagon, and GIP that has shown up to 30% weight loss and liver benefits; it could be a very large product for Lilly, with black market demand already indicating high patient interest ahead of its planned regulatory filing in early 2027.
GLP-1 / Obesity
Showing 3 of 3 calls · sorted by mentions
Choose a mentions count to open ticker posts.
Madison Muller has 3 trade ideas tracked on Buzzberg across 3 tickers since July 2026. Most covered: MRNA, MRK, LLY.
